Does ANIX pay dividends?

Anixa Biosciences Inc (ANIX) does not currently pay a regular dividend.

What is ANIX's market cap?

Anixa Biosciences Inc (ANIX) has a market capitalization of $118.40M with a current stock price of $3.35.

Anixa Biosciences Inc (ANIX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.35

-0.13 (-3.74%)

Market Cap: $118.40M

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

81%(26/32)

Avg Surprise

+7.11%

Streak

9 Q

Upcoming Estimates

Period ending Jul 31, 2026

EPS Consensus$-0.08

Range$-0.08 - $-0.08

1 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-0.09-12.5%

60d ago$-0.09-12.5%

30d ago$-0.09-12.5%

7d ago$-0.09-12.5%

Current$-0.08

Revenue Consensus

Range$0 - $0

4 analysts

Period ending Oct 31, 2026

EPS Consensus$-0.04

Range$-0.04 - $-0.04

1 analysts

Revenue Consensus

Range$0 - $0

4 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Oct 31, 2026Oct 26EST	-	$-0.04	$-0.04 - $-0.04	-	-	1	-	-
Jul 31, 2026Jul 26EST	-	$-0.08	$-0.08 - $-0.08	-	-	1	1 0 30d	-
Apr 30, 2026Apr 26 Reported Jun 10, 2026Reported Jun 10	$-0.07	$-0.10	$-0.10 - $-0.10	+30.00%	Beat	1	No revisions (30d)	+22.2%
Jan 31, 2026Jan 26 Reported Mar 9, 2026Reported Mar 9	$-0.08	$-0.09	$-0.10 - $-0.08	+11.11%	Beat	2	No revisions (30d)	+20.0%
Oct 31, 2025Oct 25 Reported Jan 12, 2026Reported Jan 12	$-0.08	$-0.08	$-0.08 - $-0.08	+3.96%	Beat	1	1 0 30d	+11.1%
Jul 31, 2025Jul 25 Reported Sep 10, 2025Reported Sep 10	$-0.07	$-0.10	$-0.10 - $-0.10	+30.00%	Beat	1	1 0 30d	+30.0%
Apr 30, 2025Apr 25 Reported May 28, 2025Reported May 28	$-0.09	$-0.10	$-0.10 - $-0.10	+10.00%	Beat	1	1 0 30d	+10.0%
Jan 31, 2025Jan 25 Reported Mar 11, 2025Reported Mar 11	$-0.10	$-0.10	$-0.10 - $-0.10	+0.00%	Beat	1	1 0 30d	+0.0%
Oct 31, 2024Oct 24 Reported Jan 10, 2025Reported Jan 10	$-0.09	$-0.11	$-0.11 - $-0.11	+18.18%	Beat	1	0 1 30d	+0.0%
Jul 31, 2024Jul 24 Reported Sep 6, 2024Reported Sep 6	$-0.10	$-0.11	$-0.11 - $-0.08	+9.09%	Beat	2	No revisions (30d)	-25.0%
Apr 30, 2024Apr 24 Reported Jun 4, 2024Reported Jun 4	$-0.10	$-0.11	$-0.11 - $-0.11	+9.09%	Beat	1	No revisions (30d)	-42.9%
Jan 31, 2024Jan 24 Reported Mar 12, 2024Reported Mar 12	$-0.10	$-0.09	$-0.09 - $-0.09	-11.11%	Miss	1	No revisions (30d)	-25.0%
Oct 31, 2023Oct 23 Reported Jan 16, 2024Reported Jan 16	$-0.09	$-0.09	$-0.09 - $-0.09	+0.00%	Beat	0	No revisions (30d)	+25.0%
Jul 31, 2023Jul 23 Reported Sep 6, 2023Reported Sep 6	$-0.08	$-0.09	$-0.09 - $-0.09	+11.11%	Beat	1	No revisions (30d)	+11.1%
Apr 30, 2023Apr 23 Reported Jun 14, 2023Reported Jun 14	$-0.07	$-0.11	$-0.12 - $-0.11	+36.36%	Beat	2	No revisions (30d)	+41.7%
Jan 31, 2023Jan 23 Reported Mar 16, 2023Reported Mar 16	$-0.08	$-0.16	$-0.16 - $-0.16	+50.00%	Beat	1	No revisions (30d)	+38.5%
Oct 31, 2022Oct 22 Reported Jan 4, 2023Reported Jan 4	$-0.12	$-0.11	$-0.13 - $-0.09	-9.09%	Miss	2	No revisions (30d)	+7.7%
Jul 31, 2022Jul 22 Reported Sep 9, 2022Reported Sep 9	$-0.09	$-0.13	$-0.13 - $-0.13	+30.77%	Beat	1	No revisions (30d)	+35.7%
Apr 30, 2022Apr 22 Reported Jun 10, 2022Reported Jun 10	$-0.12	$-0.13	$-0.13 - $-0.13	+7.69%	Beat	1	No revisions (30d)	-50.0%
Jan 31, 2022Jan 22 Reported Mar 11, 2022Reported Mar 11	$-0.13	$-0.13	$-0.13 - $-0.13	+0.00%	Beat	1	No revisions (30d)	-85.7%
Oct 31, 2021Oct 21 Reported Jan 4, 2022Reported Jan 4	$-0.13	$-0.09	$-0.09 - $-0.09	-44.44%	Miss	1	No revisions (30d)	-44.4%
Jul 31, 2021Jul 21 Reported Sep 1, 2021Reported Sep 1	$-0.14	$-0.08	$-0.08 - $-0.08	-75.00%	Miss	1	No revisions (30d)	-27.3%
Apr 30, 2021Apr 21 Reported Jun 10, 2021Reported Jun 10	$-0.08	$-0.10	$-0.12 - $-0.09	+20.00%	Beat	2	No revisions (30d)	+33.3%
Jan 31, 2021Jan 21 Reported Mar 11, 2021Reported Mar 11	$-0.07	$-0.11	$-0.11 - $-0.11	+36.36%	Beat	1	No revisions (30d)	+46.2%
Oct 31, 2020Oct 20 Reported Jan 7, 2021Reported Jan 7	$-0.09	$-0.10	$-0.11 - $-0.10	+10.00%	Beat	2	No revisions (30d)	+10.0%
Jul 31, 2020Jul 20 Reported Sep 8, 2020Reported Sep 8	$-0.11	$-0.12	$-0.13 - $-0.12	+8.33%	Beat	2	No revisions (30d)	+0.0%
Apr 30, 2020Apr 20 Reported Jun 9, 2020Reported Jun 9	$-0.12	$-0.13	$-0.13 - $-0.12	+7.69%	Beat	2	No revisions (30d)	+7.7%
Jan 31, 2020Jan 20 Reported Mar 9, 2020Reported Mar 9	$-0.13	$-0.13	$-0.13 - $-0.13	+0.00%	Beat	1	No revisions (30d)	+43.5%
Oct 31, 2019Oct 19 Reported Jan 9, 2020Reported Jan 9	$-0.10	N/A	-	+58.33%	Beat	1	No revisions (30d)	+61.5%
Jul 31, 2019Jul 19 Reported Sep 6, 2019Reported Sep 6	$-0.11	N/A	-	+52.17%	Beat	1	No revisions (30d)	+63.3%
Apr 30, 2019Apr 19 Reported Jun 11, 2019Reported Jun 11	$-0.13	$-0.23	$-0.23 - $-0.23	+43.48%	Beat	1	No revisions (30d)	-62.5%
Jan 31, 2019Jan 19 Reported Mar 13, 2019Reported Mar 13	$-0.23	$-0.15	$-0.15 - $-0.15	-53.33%	Miss	1	No revisions (30d)	-109.1%
Oct 31, 2018Oct 18 Reported Jan 11, 2019Reported Jan 11	$-0.26	$-0.15	$-0.15 - $-0.15	-73.33%	Miss	1	No revisions (30d)	-116.7%
Jul 31, 2018Jul 18 Reported Sep 7, 2018Reported Sep 7	$-0.30	N/A	-	N/A	Beat	-	-	-143.5%
Apr 30, 2018Apr 18 Reported Jun 11, 2018Reported Jun 11	$-0.08	N/A	-	N/A	Beat	-	-	-500.0%
Jan 31, 2018Jan 18 Reported Mar 9, 2018Reported Mar 9	$-0.11	N/A	-	N/A	Beat	-	-	+73.2%
Oct 31, 2017Oct 17 Reported Jan 9, 2018Reported Jan 9	$-0.12	$-0.12	-	+0.00%	Beat	-	-	-0.3%
Jul 31, 2017Jul 17 Reported Sep 8, 2017Reported Sep 8	$-0.12	N/A	-	N/A	Beat	-	-	-
Apr 30, 2017Apr 17 Reported May 26, 2017Reported May 26	$0.02	N/A	-	N/A	Beat	-	-	-
Jan 31, 2017Jan 17 Reported Mar 16, 2017Reported Mar 16	$-0.41	N/A	-	N/A	Beat	-	-	-
Oct 31, 2016Oct 16 Reported Dec 7, 2016Reported Dec 7	$-0.12	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-11.17	EV/EBITDA	-8.76x
Price/FCF	-15.81x	FCF Yield	-6.32%
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-72.00%	ROIC	-58.08%
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	9.79x	Quick Ratio	9.79x
Trading Statistics
Beta	0.52	Avg Volume	231.19K
52-Week High	$5.46	52-Week Low	$2.32

Technical Indicators Dashboard

Moving Averages

SMA 10$3.58

SMA 20$3.45

SMA 50$3.31

SMA 200$3.19

EMA 10$3.51

EMA 20$3.48

EMA 50$3.32

EMA 200$3.16

MACD

Line: 0.06Signal: 0.08Hist: -0.02

ADX

ADX: 19.8+DI: 18.5-DI: 18.9

Aroon & PSAR

Aroon Up84.0

Aroon Down56.0

PSAR$3.87

Bollinger Bands

Upper Band$3.80

Lower Band$3.10

%B Position2006%(Upper)

Band Width0.36

RSI (14-Day)

Neutral

46.3

Momentum Oscillators

Stoch %K48.8

Stoch %D58.7

Williams %R-67.6

ROC (10d)-4.0%

Momentum-0.14

CCI (20d)-15.8

MFI (14d)49.7

Volatility Measures

ATR (14d)$0.23(6.8%)

StdDev (20d)0.17

Hist Vol57.4%(High)

Volume Flow

VWAP$3.43

OBV-798.1K

AD Line-1.0M

CMF (20d)-0.211

Volume Metrics

Avg Vol (20d)235.3K

Vol Ratio1.5x

VWMA (20d)$3.50

Pivot Points

R3$3.88

R2$3.77

R1$3.63

Pivot Point$3.52

S1$3.38

S2$3.27

S3$3.13

Advanced Oscillators

TSI9.54

Ultimate Osc40.2

KST60.43

Financial Data

Quarter	Apr 2026	Jan 2026	Oct 2025	Jul 2025	Apr 2025	Jan 2025	Oct 2024	Jul 2024	Apr 2024	Jan 2024	Oct 2023	Jul 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$156,000	$0
Cost of Revenue	$0	$0	$9,000	$0	$0	$0	$0	$0	$0	$0	$12,000	$0
Gross Profit	$0	$0	$-9,000	$0	$0	$0	$0	$0	$0	$0	$144,000	$0

Operating Expenses	$2.65M	$2.72M	$2.88M	$2.44M	$3.00M	$3.39M	$3.16M	$3.59M	$3.47M	$3.61M	$3.05M	$2.84M
R&D	$1.26M	$1.10M	$1.14M	$1.05M	$1.32M	$1.55M	$1.48M	$1.93M	$1.65M	$1.35M	$1.61M	$1.09M
SG&A	$1.39M	$1.61M	$1.73M	$1.38M	$1.68M	$1.83M	$1.69M	$1.67M	$1.82M	$2.26M	$1.44M	$1.76M
Operating Income	$-2,647,000	$-2,716,000	$-2,876,000	$-2,436,000	$-3,003,000	$-3,386,000	$-3,163,000	$-3,592,000	$-3,467,000	$-3,609,000	$-3,051,000	$-2,844,000

Interest Income	$111,000	$131,000	$154,000	$156,000	$190,000	$173,000	$250,000	$277,000	$287,000	$319,000	$330,000	$296,000
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-2,536,000	$-2,585,000	$-2,722,000	$-2,280,000	$-2,813,000	$-3,213,000	$-2,913,000	$-3,315,000	$-3,180,000	$-3,290,000	$-2,721,000	$-2,548,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-2,536,000	$-2,585,000	$-2,722,000	$-2,280,000	$-2,813,000	$-3,213,000	$-2,913,000	$-3,315,000	$-3,180,000	$-3,290,000	$-2,721,000	$-2,548,000

EBITDA	$-2,613,000	$-2,659,000	$-2,917,000	$-2,441,000	$-2,821,000	$-3,629,000	$-3,154,000	$-3,589,000	$-3,455,000	$-3,596,000	$-3,039,000	$-2,833,000
EBIT	$-2,647,000	$-2,716,000	$-2,876,000	$-2,436,000	$-3,003,000	$-3,386,000	$-3,163,000	$-3,592,000	$-3,467,000	$-3,609,000	$-3,051,000	$-2,844,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about ANIX

News

Anixa Biosciences Inc (NASDAQ:ANIX) Given Consensus Recommendation of "Hold" by Brokerages

Anixa Biosciences Inc (NASDAQ:ANIX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $8.50. The company recently reported a quarterly loss of $0.07 per share, beating analyst estimates. Notably, insiders and institutions hold significant stakes, with CEO Amit Kumar recently increasing his shares.

MarketBeat•Aug 26, 2026 10:10 AM8/26/26•

Neutral

Breast cancer vaccine meets Phase 1 goals; ovarian cancer CAR-T shows promising survival in Phase 1 trial

Anixa Biosciences announced successful Phase 1 results for its breast cancer vaccine, achieving primary endpoints and immune responses in 74% of participants, with Phase 2 preparations underway. Their ovarian cancer CAR-T therapy, lira-cel, also showed promising results in its ongoing Phase 1 trial, reaching the highest dose level without dose-limiting toxicities and extending survival beyond one year in four patients. These advancements highlight Anixa's progress in cancer immunotherapy, with upcoming presentations at the 2026 Cantor Fitzgerald Global Healthcare Conference.

Pluang•Aug 24, 2026 12:41 PM8/24/26•

Bullish

Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Anixa Biosciences announced it will present at the 2026 Cantor Fitzgerald Global Healthcare Conference to discuss its clinical progress in cancer treatment and prevention. The presentation will highlight the positive Phase 1 results of its breast cancer vaccine, developed with Cleveland Clinic, which met all primary endpoints and is moving towards Phase 2. Additionally, Anixa will update on its ovarian cancer CAR-T therapy, lira-cel, being developed with Moffitt Cancer Center, noting that the trial has advanced to the highest dose level with lymphodepletion and some patients have achieved over one year of survival.

PR Newswire•Aug 24, 2026 12:41 PM8/24/26•

Bullish

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

Anixa Biosciences (ANIX) has received an upgrade to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates. This change signals an improvement in the company's underlying business, which is expected to favorably impact its stock price. The Zacks Rank system, which correlates earnings estimate revisions with stock movements, places ANIX in the top 5% of covered stocks.

Eastern Progress•Aug 22, 2026 6:10 AM8/22/26•

Bullish

Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks

This article highlights three noteworthy penny stocks: Anixa Biosciences (ANIX), Organogenesis Holdings (ORGO), and Kaltura (KLTR), discussing their financial health, recent developments, and market positions. Anixa Biosciences is advancing in oncology treatments with promising clinical trials, Organogenesis Holdings faces financial challenges despite positive trial results, and Kaltura shows progress in reducing losses with innovative product developments. The article emphasizes that while the broader market has been flat recently, these companies offer potential growth and value for investors looking at smaller, fundamentally strong firms.

Simply Wall Street•Aug 21, 2026 5:18 PM8/21/26•

Bullish

Frequently Asked Questions About ANIX

Does ANIX pay dividends?: Anixa Biosciences Inc (ANIX) does not currently pay a regular dividend.
What is ANIX's market cap?: Anixa Biosciences Inc (ANIX) has a market capitalization of $118.40M with a current stock price of $3.35.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In